FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2326350312> ?p ?o ?g. }

• W2326350312 endingPage "84" @default.
• W2326350312 startingPage "1977" @default.
• W2326350312 abstract "The clinical benefit of an intensive follow-up protocol in endometrial cancer patients is still uncertain.One hundred and thirty-three patients underwent initial abdominal surgery for clinical stage I endometrial cancer between January 1988 and December 1997 and were periodically followed-up until April 1999 or until death. After surgery, 89 patients received postoperative adjuvant treatment. Periodical surveillance included physical examination, vaginal smear and abdominal-pelvic ultrasound every 3-4 months for the first 2 years from surgery, every 6 months for the next 3 years and yearly thereafter. Chest X-ray was performed every 6 months for the first 2 years, every year for the next 3 years and with individually increasing intervals afterwards. An abdominal-pelvic CT scan was carried out yearly for 5 years.Twenty-four patients (18.0%) developed recurrent disease after a median time of 17.5 months (range, 6-64 months). Five-year actuarial disease-free survival was 81.2% in the whole series, and in detail 94.2% in the subset of patients with FIGO stage Ia grade 1 or 2 endometrioid adenocarcinoma, or stage Ib grade 1 endometrioid adenocarcinoma (low-risk), compared to 76.0 (p = 0.0472) in the subset of patients with stage Ia grade 3 endometrioid adenocarcinoma, stage Ib grade 2 or 3 endometrioid adenocarcinoma, stage equal to or greater than Ic endometrioid adenocarcinoma any grade, and aggressive histologies (high-risk). The site of recurrent disease was local in 6 (25.0%) patients, distant in 17 (70.8%), and local plus distant in 1 (4.2%). Eleven (45.8%) recurrences were symptomatic and 13 (54.2%) were asymptomatic. The median survival after recurrence was 10 months. Survival was longer in patients who relapsed after 17.5 months from initial surgery when compared to those who relapsed earlier (p = 0.02). Conversely, survival after recurrence was not related to patient characteristics at diagnosis, such as FIGO stage, tumor grade, myometrial invasion, histologic type, and lymph node status. It is noteworthy that survival was similar in asymptomatic women, in whom the relapse was occasionally detected by follow-up examinations, and in symptomatic ones.An intensive surveillance protocol seems to have no significant impact on the outcome of patients with clinical stage I endometrial cancer. Simplified follow-up programs tailored for patient subsets with different recurrence risk are required." @default.
• W2326350312 created "2016-06-24" @default.
• W2326350312 creator A5006447422 @default.
• W2326350312 creator A5044979512 @default.
• W2326350312 creator A5069459412 @default.
• W2326350312 creator A5072913865 @default.
• W2326350312 creator A5087102751 @default.
• W2326350312 date "2000-08-06" @default.
• W2326350312 modified "2023-09-23" @default.
• W2326350312 title "An intensive follow-up does not change survival of patients with clinical stage I endometrial cancer." @default.
• W2326350312 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10928137" @default.
• W2326350312 hasPublicationYear "2000" @default.
• W2326350312 type Work @default.
• W2326350312 sameAs 2326350312 @default.
• W2326350312 citedByCount "22" @default.
• W2326350312 countsByYear W23263503122012 @default.
• W2326350312 countsByYear W23263503122013 @default.
• W2326350312 countsByYear W23263503122014 @default.
• W2326350312 countsByYear W23263503122018 @default.
• W2326350312 countsByYear W23263503122019 @default.
• W2326350312 countsByYear W23263503122020 @default.
• W2326350312 countsByYear W23263503122021 @default.
• W2326350312 countsByYear W23263503122022 @default.
• W2326350312 countsByYear W23263503122023 @default.
• W2326350312 crossrefType "journal-article" @default.
• W2326350312 hasAuthorship W2326350312A5006447422 @default.
• W2326350312 hasAuthorship W2326350312A5044979512 @default.
• W2326350312 hasAuthorship W2326350312A5069459412 @default.
• W2326350312 hasAuthorship W2326350312A5072913865 @default.
• W2326350312 hasAuthorship W2326350312A5087102751 @default.
• W2326350312 hasConcept C121608353 @default.
• W2326350312 hasConcept C126322002 @default.
• W2326350312 hasConcept C141071460 @default.
• W2326350312 hasConcept C146357865 @default.
• W2326350312 hasConcept C151730666 @default.
• W2326350312 hasConcept C2777088508 @default.
• W2326350312 hasConcept C2781182431 @default.
• W2326350312 hasConcept C71924100 @default.
• W2326350312 hasConcept C86803240 @default.
• W2326350312 hasConceptScore W2326350312C121608353 @default.
• W2326350312 hasConceptScore W2326350312C126322002 @default.
• W2326350312 hasConceptScore W2326350312C141071460 @default.
• W2326350312 hasConceptScore W2326350312C146357865 @default.
• W2326350312 hasConceptScore W2326350312C151730666 @default.
• W2326350312 hasConceptScore W2326350312C2777088508 @default.
• W2326350312 hasConceptScore W2326350312C2781182431 @default.
• W2326350312 hasConceptScore W2326350312C71924100 @default.
• W2326350312 hasConceptScore W2326350312C86803240 @default.
• W2326350312 hasIssue "3B" @default.
• W2326350312 hasLocation W23263503121 @default.
• W2326350312 hasOpenAccess W2326350312 @default.
• W2326350312 hasPrimaryLocation W23263503121 @default.
• W2326350312 hasRelatedWork W1968940509 @default.
• W2326350312 hasRelatedWork W1981749241 @default.
• W2326350312 hasRelatedWork W2057743303 @default.
• W2326350312 hasRelatedWork W2182739404 @default.
• W2326350312 hasRelatedWork W2207422528 @default.
• W2326350312 hasRelatedWork W2326350312 @default.
• W2326350312 hasRelatedWork W2352349801 @default.
• W2326350312 hasRelatedWork W2392677812 @default.
• W2326350312 hasRelatedWork W2624074734 @default.
• W2326350312 hasRelatedWork W2898264974 @default.
• W2326350312 hasVolume "20" @default.
• W2326350312 isParatext "false" @default.
• W2326350312 isRetracted "false" @default.
• W2326350312 magId "2326350312" @default.
• W2326350312 workType "article" @default.